APC and neoplasm: Although loss of PKD1 does not differentially affect the response of organoids or tumors to cytotoxic regimens, the lower baseline of tumors in Apc−/−Pkd1−/− mice results in a more effective reduction in total tumor burden following treatment with these agents.